Agilent Technologies Files 2024 Annual Report

TL;DR

Agilent's 2024 10-K is in, check financials and future outlook.

AI Summary

Agilent Technologies, Inc. filed its 10-K for the fiscal year ending October 31, 2024. The company, headquartered in Santa Clara, CA, operates in the laboratory analytical instruments sector. Key financial details and business operations for the period are outlined in this comprehensive annual report.

Why It Matters

This filing provides investors and stakeholders with a detailed overview of Agilent's financial performance, strategic initiatives, and risk factors for the fiscal year 2024.

Risk Assessment

Risk Level: medium — The filing contains standard disclosures for a public company, including business operations, financial statements, and risk factors, which are typical for a company of this size and industry.

Key Players & Entities

• AGILENT TECHNOLOGIES, INC. (company) — Filer
• 20241031 (date) — Fiscal Year End
• 20241220 (date) — Filing Date
• Santa Clara, CA (location) — Business Address

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value A New York Stock Exchange S

Filing Documents

• a-20241031.htm (10-K) — 3638KB
• a-10312024xexx191.htm (EX-19.1) — 15KB
• a-10312024xexx211.htm (EX-21.1) — 4KB
• a-10312024xexx231.htm (EX-23.1) — 2KB
• a-10312024xexx311.htm (EX-31.1) — 11KB
• a-10312024xexx312.htm (EX-31.2) — 11KB
• a-10312024xexx321.htm (EX-32.1) — 6KB
• a-10312024xexx322.htm (EX-32.2) — 6KB
• a-10312024xexx971.htm (EX-97.1) — 44KB
• a-20241031_g1.jpg (GRAPHIC) — 129KB
• 0001090872-24-000049.txt ( ) — 20638KB
• a-20241031.xsd (EX-101.SCH) — 81KB
• a-20241031_cal.xml (EX-101.CAL) — 90KB
• a-20241031_def.xml (EX-101.DEF) — 851KB
• a-20241031_lab.xml (EX-101.LAB) — 1365KB
• a-20241031_pre.xml (EX-101.PRE) — 1134KB
• a-20241031_htm.xml (XML) — 4186KB

Forward-Looking Statements

Forward-Looking Statements 3 PART I Item 1

Business

Business 3 Item 1A

Risk Factors

Risk Factors 17 Item 1B Unresolved Staff Comments 29 Item 1C Cybersecurity 29 Item 2

Properties

Properties 30 Item 3

Legal Proceedings

Legal Proceedings 30 Item 4 Mine Safety Disclosures 30 PART II Item 5 Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 31 Item 6 [Reserved] 32 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 32 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 56 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 57 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 120 Item 9A

Controls and Procedures

Controls and Procedures 120 Item 9B Other Information 120 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 120 PART III Item 10 Directors, Executive Officers and Corporate Governance 121 Item 11

Executive Compensation

Executive Compensation 121 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 121 Item 13 Certain Relationships and Related Transactions, and Director Independence 122 Item 14 Principal Accounting Fees and Services 122 PART IV Item 15 Exhibits and Financial Statement Schedules 123 Item 16 Form 10-K Summary 128

Signatures

Signatures 129 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements including, without limitation, statements regarding growth opportunities, including for and in our end markets, new product and service introductions, the position and strength of our businesses, products and services, market demand for and adoption of our products and solutions, the ability of our products and solutions to address customer needs and meet industry requirements, our focus on enhancing our customers' experience, delivering differentiated product solutions and driving productivity improvements, our investments, including in manufacturing infrastructure, research and development and expanding and improving our applications and solutions portfolios, expanding our position in developing countries and emerging markets, our contributions to our defined benefit plans, our hedging programs and other actions to offset the effects of foreign currency and interest rate movements, our future effective tax rate, unrecognized tax benefits, reimbursement incentives, our ability to satisfy our liquidity requirements, including through cash generated from operations, the potential impact of adopting new accounting pronouncements, indemnification obligations, our sales, our purchase commitments, our capital expenditures, the integration, effects and timing of our acquisitions and other transactions, expense reduction and other results from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic and market conditions, the recovery and health of our end markets, seasonality, mix, future financial results, our operating margin, our geographical diversification, interest rates, inflationary pressures and local regulations and restrictions, that involve risks and uncertainties. Our actual results could differ materially from the results contemplated by these forward-looking statements due to various factors, including those discussed i

Business

Item 1. Business Overview Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In the first quarter of fiscal year 2024, we announced a change in our operating segments to move our cell analysis business from our life sciences and applied markets segment to our diagnostics and genomics operating segment in order to further strengthen growth opportunities for both organizations. Following this reorganization, we continued to have three business segments comprised of life sciences and applied markets, diagnostics and genomics and Agilent CrossLab, each of which continues to comprise a reportable segment. All historical financial segment information has been recast to conform to this new presentation in our consolidated financial statements and accompanying notes. There was no change to our Agilent CrossLab business segment. See also Note 23, "Subsequent Event" for additional information on recent changes to our organizational structure. Our life sciences and applied markets business provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Our consumables portfolio is designed to improve customer outcomes. Our diagnostics and genomics business is comprised of seven areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas t

View Full Filing

View this 10-K filing on SEC EDGAR